Diseases
Topics  
 
 
 

NOTE: If you are having trouble viewing these pdf files in your browser try right clicking on the 'Full Text' and click 'Save Target As...' then choose a directory on your computer. You need to have Adobe Acrobat Reader to view these files.


HIV

  • D.P. Wilson, P.M. Coplan, M.A. Wainberg, and S.M. Blower. 2008. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. PNAS 105(28): 9835-40. [Full Text][Supplemental Material].

  • D.P. Wilson and S.M. Blower. 2007. How far will we need to go to reach HIV-infected people in rural South Africa? BMC Medicine 19 (5):16. [Full Text].

  • R. Vardavas and S.M. Blower. 2007. The Emergence of HIV Transmitted Resistance in Botswana: “When Will the WHO Detection Threshold Be Exceeded?” PLoS One 1(e152).[Full Text][Supplemental Information][Press]

  • D.P. Wilson, J.O. Kahn and S.M. Blower. 2006. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban-rural divide. PNAS 103(38):14228-14233. Epub 2006 Sep 12. [Full Text] [Supplemental Information].
    Science Magazine's Editor's Choice Article in the field of Biomedicine [Link].

  • R. Breban, I. McGowan, C. Topaz, E.J. Schwartz, P. Anton and S.M. Blower. 2006. Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering 3(3):459-66. [Full Text].

  • R. Breban and S.M. Blower. 2006. The role of parametric resonance in virological failure during HIV treatment interruption therapy. The Lancet 367(9518): 1285-9. [Full Text] [Supplemental Material].

  • D.P. Wilson and S.M. Blower. 2006. Rational choices for allocating antiretrovirals in Africa: treatment equity, epidemiological efficiency, and feasibility. PLoS Medicine 3(3): e160. Epub 2006 March 28. [Full Text].

  • D.P. Wilson, E.N. Bodine, R.J. Smith and S.M. Blower. 2005. Response to Foss et al. "Care should be taken when promoting microbicide use among sex workers who are able to use condom consistently". AIDS 19(17):2044-6. [Full Text].

  • S.M. Blower. 2005. Modeling the Potential Public Health Impact of Imperfect HIV Vaccines. Journal of Infectious Diseases 192: 1494-5. [Full Text].

  • S.M. Blower, E.N. Bodine, K. Grovit-Ferbas. 2005. Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of clades. Current Drug Targets - Infectious Disorders 5(2): 179-192. [Full Text].

  • D.P. Wilson and S.M. Blower. 2005. Allocating antiretrovirals in South Africa: using modeling to determine treatment equity. PLoS Medicine 2(6): e155; author reply e186. Epub 2005 Jun 28. [Full Text].

  • S.M. Blower and R.J. Smith. 2005. Is population-level perversity a likely outcome of mass vaccination against HIV? - Author's reply. The Lancet Infectious Diseases 5(5): 255-256. [Full Text].

  • R.J. Smith, E.N. Bodine, D.P. Wilson, S.M. Blower. 2005. Evaluating the potential impact of vaginal microbicides to reduce the risk of HIV acquisition in female sex workers. AIDS 19(4): 413-421. [Full Text].

  • D.P. Wilson and S.M. Blower. 2005. Designing Equitable Antiretroviral Allocation Strategies in Resource-Constrained Countries. PLoS Medicine 2(2): 132-141. [Full Text] [Synopsis].

  • S.M. Blower, E.N. Bodine, J.O. Kahn, W. McFarland. 2005. The antiretroviral rollout & drug resistant HIV in Africa: insights from empirical data & theoretical models. AIDS 19(1): 1-14. [Full Text].

  • D.P. Wilson and S.M. Blower. 2004. Microbicides: Anti-HIV Efficacy and Ethics. Science 306(5703): 1890. [Full Text].

  • S.M. Blower and Li Ma. 2004. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clinical Infectious Diseases 39(Suppl 5): S240-S247. [Full Text].

  • R.J. Smith and S.M. Blower. 2004. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infectious Diseases 4(10): 636-39. [Full Text] [Appendix].

  • S.M. Blower, L. Ma, P. Farmer, and S. Koenig. 2003. Predicting the impact of antiretrovirals in resource poor settings: preventing HIV infections whilst controlling drug resistance. Current Drug Targets - Infectious Disorders 3: 345-353. [Full Text].

  • S.M. Blower, R.B. Moss and E. Fernandez-Cruz. 2003. Calculating the potential epidemic-level impact of therapeutic vaccination on the San Francisco HIV epidemic. AIDScience 3 (21). [Full Text].

  • S.M. Blower, E.J. Schwartz and J. Mills. 2003. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Reviews 5 (2): 113-125. [Full Text].

  • S.M. Blower and P. Farmer. 2003. Predicting the public health impact of antiretrovirals: preventing HIV in developing countries. AIDScience 3 (11). [Full Text].

  • S.M. Blower, A.N. Aschenbach and J.O. Kahn. 2003. Predicting the transmission of drug-resistant HIV: comparing theory with data. The Lancet Infectious Diseases 3 (1): 10. [Full Text].

  • S.M. Blower, K. Koelle and J. Mills. 2002. Health policy modeling: epidemic control, HIV vaccines and risky behavior. Quantitative Evaluation of HIV Prevention Programs. Eds Kaplan and Brookmeyer. Yale University Press. Pages 260-289. [Full Text].

  • S.M. Blower and P. Volberding. 2002. What can modeling tell us about the threat of antiviral drug resistance? Current Opinion in Infectious Diseases 15 (6): 609-614. [Full Text].

  • J.X. Velasco-Hernandez, H.B. Gershengorn and S.M. Blower. 2002. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? The Lancet Infectious Diseases 2: 487-493. [Full Text].

  • S.M. Blower and C.L. Daley. 2002. Problems and solutions for the Stop TB Partnership. The Lancet Infectious Diseases 2: 374-376. [Full Text].

  • S.M. Blower, K. Koelle, D.E. Kirschner and J. Mills. 2001. Live attenuated HIV vaccines: predicting the trade-off between efficacy and safety. Proceedings of the National Academy of Sciences 98 (6): 3618-3623. [Full Text].

  • S.M. Blower. 2001. Transmission of zidovudine resistant strains of HIV-1: the first wave. AIDS 15: 1-2. [Full Text].

  • S.M. Blower, A.N. Aschenbach, H.B. Gershengorn and J.O. Kahn. 2001. Predicting the unpredictable: Transmission of drug-resistant HIV. Nature Medicine 7 (9): 1016 - 1020. [Full Text] [Erratum].

  • S. M. Blower. 2001. Calculating the consequences: Highly active anti-retroviral therapy and risky sex. AIDS 15:1309-1310. [Full Text].

  • T.C. Porco and S.M. Blower. 2000. HIV Vaccines: the effect of the mode of action on the coexistence of HIV subtypes. Mathematical Population Studies 8 (2): 205-229. [Full Text].

  • S.M. Blower, H.B. Gershengorn and R.M. Grant, 2000. Reversibility of HIV drug resistance, Science 288: 1299. [Full Text].

  • S.M. Blower, H.B. Gershengorn and R.M. Grant. 2000. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650 - 654. [Full Text].

  • T.C. Porco and S.M. Blower. 1998. Designing HIV vaccination policies: subtypes and Cross-Immunity. Interfaces 28: 167-190. [Full Text].

  • S.M. Blower, S.K. Service and D.H. Osmond. 1997. Calculating the odds of HIV infection due to sexual partner selection. AIDS and Behavior 1 (4): 273-274. [Full Text].

  • S.K. Service and S.M. Blower. 1996. Linked HIV epidemics in San Francisco. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 11 (3): 311-313. [Full Text].

  • A.R. McLean and S.M. Blower. 1995. Modeling HIV vaccination. Trends in Microbiology 3 (12): 458-463. [Full Text].

  • S.K. Service and S.M. Blower. 1995. HIV transmission in sexual networks: an empirical analysis. Proceedings of the Royal Society of London, Series B, 260: 237-244. [Full Text].

  • S.M. Blower and A.R. McLean. 1995. AIDS: modeling epidemic control. Science 267 (5202): 1252-1253. [Full Text].

  • S.M. Blower and A.R. McLean. 1994. Prophylactic vaccines, risk behavior change & the probability of eradicating HIV in San Francisco. Science 265: 1451-1454. [Full Text].

  • A.R. McLean and S.M. Blower. 1993. Imperfect vaccines and herd immunity to HIV. Proceedings of the Royal Society of London, Series B, 253: 9-13. [Full Text].

If you have any comments, suggestions, or ideas regarding this site please e-mail the webmaster   Meagan Barrett.